• {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}
      • logo ubrevly
      Product Monograph
      PATIENT INFORMATION
      Important Safety Information

      UBRELVY is indicated for the acute treatment of migraine, with or without aura, in adults.

      ACHIEVE I STUDY

      DEMONSTRATED FREEDOM FROM MOST BOTHERSOME MIGRAINE-RELATED SYMPTOM (MBS) VS. PLACEBO

      2 hours after an initial dose of UBRELVY 100 mg, significantly more patients reported freedom from their most bothersome migraine-related symptom (photophobia, phonophobia, or nausea) vs. placebo.1†

      mbs-free at 2 hours
      study design button

      separator

      DEMONSTRATED FREEDOM FROM MOST BOTHERSOME MIGRAINE-RELATED SYMPTOM (MBS) VS. PLACEBO

      2 hours after an initial dose of UBRELVY 100 mg, significantly more patients reported freedom from their most bothersome migraine-related symptom (photophobia, phonophobia, or nausea) vs. placebo.1†

      mbs-free at 2 hours
      study design button

      separator

      SAFETY INFORMATION

      Click here for additional safety information and for a link to the Product Monograph discussing:

      ●Contraindications with concomitant use of strong CYP3A4 inhibitors.

      ●Relevant warnings and precautions regarding driving and operating machinery, hypersensitivity reactions, may reduce effectiveness of oral contraceptives, use in pregnant or breast-feeding women and dose selection in geriatric patients.

      ●Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

       

      FOR MORE INFORMATION

      For any questions related to UBRELVY, you can contact AbbVie Medical Information at 1-844-241-5011. 

      SAFETY INFORMATION

      Click here for additional safety information and for a link to the Product Monograph discussing:

      ●Contraindications with concomitant use of strong CYP3A4 inhibitors.

      ●Relevant warnings and precautions regarding driving and operating machinery, hypersensitivity reactions, may reduce effectiveness of oral contraceptives, use in pregnant or breast-feeding women and dose selection in geriatric patients.

      ●Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

       

      FOR MORE INFORMATION

      For any questions related to UBRELVY, you can contact AbbVie Medical Information at 1-844-241-5011. 

      SAFETY INFORMATION

      Click here for additional safety information and for a link to the Product Monograph discussing:

      ●Contraindications with concomitant use of strong CYP3A4 inhibitors.

      ●Relevant warnings and precautions regarding driving and operating machinery, hypersensitivity reactions, may reduce effectiveness of oral contraceptives, use in pregnant or breast-feeding women and dose selection in geriatric patients.

      ●Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

       

      FOR MORE INFORMATION

      For any questions related to UBRELVY, you can contact AbbVie Medical Information at
      1-844-241-5011. 

      †Most bothersome symptom (MBS) freedom was defined as the absence of the self-identified MBS, other than headache pain (i.e., photophobia, phonophobia, or nausea) 2 hours after the initial dose.

      ‡Modified intent-to-treat (mITT) population included all randomized patients who received at least 1 dose of investigational product, recorded a baseline migraine headache severity measurement, and had ≥1 post-dose migraine headache severity measurement at or before the 2-hour timepoint.

      Reference:

      1. UBRELVY (ubrogepant) Product Monograph. AbbVie Corporation. 

      UBRELVY and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation. 

      © 2024 AbbVie. All rights reserved. 

      CA-UBR-230004A / JN24  

      UBRELVY and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation. 

      © 2024 AbbVie. All rights reserved. 

      CA-UBR-230004A / JN24  

      ABOUT THIS STUDY1…

      ●ACHIEVE I was a randomized, double-blind, placebo-controlled, single migraine attack study. Patients were randomized to UBRELVY 50 mg (n=423) or 100 mg (n=448) or placebo (n=456).

      ●This study enrolled patients with a history of migraine with and without aura who experienced 2 to 8 migraine attacks per month with moderate to severe headache pain.

      ●Patients were permitted to use standard migraine preventive medications during the study.

      ●Patients were instructed to treat a migraine with moderate to severe headache pain intensity within the first 4 hours of pain onset.

      ●An optional second dose of medication or the patient’s usual acute treatment for migraine was allowed 2 to 48 hours after the initial treatment for a non-responding or recurrent migraine headache. Results shown reflect response after the single initial dose only.

       

      Reference:

      1. UBRELVY (ubrogepant) Product Monograph. AbbVie Corporation. 

      ABOUT THIS STUDY1…

      ●ACHIEVE I was a randomized, double-blind, placebo-controlled, single migraine attack study. Patients were randomized to UBRELVY 50 mg (n=423) or 100 mg (n=448) or placebo (n=456).

      ●This study enrolled patients with a history of migraine with and without aura who experienced 2 to 8 migraine attacks per month with moderate to severe headache pain.

      ●Patients were permitted to use standard migraine preventive medications during the study.

      ●Patients were instructed to treat a migraine with moderate to severe headache pain intensity within the first 4 hours of pain onset.

      ●An optional second dose of medication or the patient’s usual acute treatment for migraine was allowed 2 to 48 hours after the initial treatment for a non-responding or recurrent migraine headache. Results shown reflect response after the single initial dose only.

       

      Reference:

      1. UBRELVY (ubrogepant) Product Monograph. AbbVie Corporation. 

      This website is intended for Canadian Healthcare Professionals

      Copyright® 2022 AbbVie Corporation. Canada. 

      Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.